Nattokinase

Also known as: natto enzyme, subtilisin NAT, NSK-SD

Confidence

research strength

CLimited confidence456 studies referenced

Latest evidence update: 2026-01-29

Strongest in Study quality (65). Held back by Replication (27).

Study quality (37%)

Study design (21%)

Risk of bias (16%)

Solid mix of RCTs with some methodological gaps.

Replication (26%)

Cross-study replication (21%)

Precision (5%)

Few independent replications; results not yet robust.

Sample size (16%)

Small combined sample; treat as preliminary.

Consistency (11%)

Mixed direction across studies.

Recency (10%)

Evidence base skews older; field may have moved on.

Effect by outcome

how big the change is

No quantified outcomes yet. Once we have studies with measurable endpoints, you will see per-outcome magnitude here.

Cardiovascular health

Common dosage

2000-4000 FU daily

Description

Fibrinolytic enzyme derived from natto (fermented soybean). Evidence for reducing blood clot formation, lowering blood pressure, and improving circulation. Unique mechanism of action distinct from other cardiovascular supplements.

Safety & interactions

Do NOT combine with blood thinners (warfarin, aspirin). Discontinue 2 weeks before surgery. Contraindicated in bleeding disorders.

Check interactions with other supplements→

Some links on this page may earn us a commission at no extra cost to you. This never influences our evidence grades or recommendations. Full disclosure

Order Nattokinase

Recommended: 2000-4000 FU daily

Questions about Nattokinase

Who has been studied for Nattokinase?

Who should avoid Nattokinase based on the safety notes?

What dose did studies use for Nattokinase, and when was it taken?

Referenced studies (6)

ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.